BioSpace News Archive

CANbridge Pharmaceuticals Inc. (HKEX:1228), announced that the first patient has been dosed in the CAN103 Phase 1/2 trial in treatment-naïve patients with Gaucher disease (GD) Types I and III in China.

Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), today announced the pricing of its firm commitment initial public offering of 1,350,000 ordinary shares at a public offering price of $5.00 per share, for total gross proceeds of $6.75 million, before deducting underwriting discounts, commissions, and other related expenses.

Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), announced today that the results of its successful Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) has been published in the Journal of the American Medical Association (JAMA) Dermatology.

Neogen Corporation held a ceremonial groundbreaking in anticipation of approvals on a $70 million expansion of their Lansing, Michigan, food safety facility.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company’s vision of creating a healthier world for all people.

Brainomix, the AI-powered medtech solutions company, today announces that it has appointed Melissa Strange as Chief Financial Officer (CFO) and Jérôme Galbrun as Chief Revenue Officer (CRO).

Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces receiving its second patent for a novel cyclosporine dry eye therapy.

According to the report, the global pulse electromagnetic field (PEMF) therapy devices market was valued at US$ 550 Mn in 2020 and is anticipated to expand at a CAGR of 3% from 2022 to 2030.

As COVID-19 continues to have catastrophic effects on the lives of human beings throughout the world, healthcare facilities are under scrutiny for providing proper care and diagnosis for patients.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Tuesday, August 2, 2022.